Can the new drug Bedaquiline be reimbursed by medical insurance?

Bedaquiline (Bedaquiline), as a new anti-tuberculosis drug, has been approved and put into use in many countries around the world, playing an important role in the treatment of multi-drug-resistant tuberculosis (MDR-TB). In China, bedaquiline is produced by bedaquiline fumarate tablets (trade name: Sneril) and has been included in the scope of medical insurance. This means that eligible patients can be reimbursed for part of the cost through medical insurance when treated with bedaquiline, thereby reducing the patient's financial burden.

The common specifications of bedaquiline are100mg*24 tablets per box, and the price is about 10,000 yuan. Due to the high production cost and relatively high price of bedaquiline, the wide application of this drug is limited in some areas with poor economic conditions. The inclusion of medical insurance provides more affordable treatment options for eligible MDR-TB patients, helping them obtain the drug treatment they need with less financial pressure.

However, bedaquiline’s medical insurance reimbursement is not applicable to all patients. It is limited to those patients diagnosed with multi-drug-resistant tuberculosis, and patients need to meet certain conditions to obtain medical insurance reimbursement. Therefore, before using bedaquiline, patients must be evaluated and confirmed by a professional doctor to ensure that the drug is suitable for their condition.

The inclusion of bedaquiline in medical insurance will have a positive impact on China's public health management of anti-tuberculosis treatment. China is one of the countries with a high incidence of tuberculosis, and the number of cases of multi-drug-resistant tuberculosis is increasing year by year. As an effective therapeutic drug, bedaquiline provides an important therapeutic weapon to deal with the challenge of multi-drug-resistant tuberculosis. Through the support of medical insurance, patients can obtain the drug, thereby improving the treatment effect and patient survival rate.

Reference materials:https://en.wikipedia.org/wiki/Bedaquiline